SMRČKA, Martin, Jiří ŠÁNA, Radek LAKOMÝ, Pavel FADRUS, Pavel ŠLAMPA, Leoš KŘEN, Marek SVOBODA, Marian HAJDUCH and Ondřej SLABÝ. MicroRNA signature associated with poor outcome of glioblastoma patients. In 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. 2014.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MicroRNA signature associated with poor outcome of glioblastoma patients
Authors SMRČKA, Martin (203 Czech Republic, guarantor, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Pavel FADRUS (203 Czech Republic, belonging to the institution), Pavel ŠLAMPA (203 Czech Republic, belonging to the institution), Leoš KŘEN (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Marian HAJDUCH (203 Czech Republic) and Ondřej SLABÝ (203 Czech Republic, belonging to the institution).
Edition 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, 2014.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/14:00080178
Organization unit Faculty of Medicine
Keywords in English MicroRNA; glioblastoma
Tags EL OK, podil
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 16. 3. 2015 11:03.
Abstract
BACKGROUND: It is very important to find new biomarkers which can predict clinical outcomes of glioblastoma (GBM) and help in treatment decissions. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play key role in pathogenesis of wide range of cancer. Aim of our study is to identify miRNA signature associated with the more aggressive phenotype of GBMs, which will enable sensitive prediction of clinical outcome in GBM patients. METHODS: We determined the expression profile of 667 miRNAs in tumor tissues of 58 patients with primary GBM with completed concomitant chemoradiotherapy with temozolomide and 12 non-malignant brain tissues obtained from patients with drug-resistant anteromedial temporal lobe epilepsy. Methylation status of MGMT promoter (methylation-specific HRM), isocitrate dehydrogenase (IDH1) status (immunohistochemistry) and co-deletion of 1p/19q (FISH) was also evaluated. RESULTS: We have confirmed frequencies of commonly used prognostic biomarkers in GBM patients (MGMT, IDH1, 1p/19q deletion), and observed significant correlation of MGMT methylation status, response to chemoradiotherapy with temozolomide and survival of GBM patients. We have identified specific signature of miRNAs diferentially expressed between GBM tissue and non-tumoral brain tissue from epilepsy surgeries (28 miRNAs, p<10-10). We have confirmed some previous observations (e.g. up-regulation of miR-21, miR-155, down-regulation of miR-128a, miR-23a) and also identified miRNAs deregulated in GBM tissue which were observed for the first time (e.g. miR-220, miR-328, miR-888, miR-504). More importantly we have found miRNA signature (miR-224, miR-31, miR-454, miR-672, miR-885-5p, miR-432) significantly associated short progression-free survival (p<10-6) and overall survival (p<10-6). CONCLUSIONS: These findings indicate that miRNAs play an important role in GBM pathogenesis and may serve not only as promising predictors of therapeutic outcome but also as potential therapeutic targets in GBM patients.
Links
NT13514, research and development projectName: Analýza mikroRNA v glioblastomových kmenových buňkách: predikce léčebné odpovědi a identifikace nových terapeutických cílů u pacientů s glioblastomem
NT13549, research and development projectName: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem
PrintDisplayed: 21. 5. 2022 21:04